{'fraction_non_alphanumeric': 0.03241106719367589, 'fraction_numerical': 0.007905138339920948, 'mean_word_length': 5.393939393939394, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lugrandoside attenuates spinal cord injury by targeting peli1 and TLR4/NF-κB pathway to exert anti-inflammatory and anti-apoptotic effects

Purpose: To investigate the curative effect and mechanism of lugrandoside (LG) on spinal cord injury (SCI).Methods: We probed the expression of Pellino1 (peli1) in microglia and spinal cord tissues withdifferent treatments of LG. Lipopolysaccharide (LPS) was used to activate the microglia. Furthermore, rats were used to establish SCI model, and LG, at low and high concentrations, was administered to injured animals to ascertain whether LG exerted a therapeutic effect on SCI.Results: LG inhibited the activation and recruitment of glial cells by acting as a negative regulator of glial inflammation, and this reverse the targeting of peli1 and TLR4/NF-κB pathway. Furthermore, the in vivo data showed that LG exerted a neuroprotective effect, following SCI, via anti-inflammatory and antiapoptotic effects. Furthermore, Peli1 and TLR4/NF-κB were suppressed by LG stimuli.Conclusion: These results suggest that LG protects neural tissue against neuroinflammation and apoptosis by suppressing TLR4/NF-κB pathway and negatively targeting peli1. The findings may provide new insights into the treatment of spinal cord injury.